IKT
Inhibikase Therapeutics Inc
2.10$
-1.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -100.0% | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | 0.0% | 0.0% | +92.7% | +90.9% | -1.9% | +55.4% | – | – | – | |
| – | -109.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | -6.9% | -8.4% | +11.8% | +36.2% | +71.5% | +46.3% | -49.9% | +45.1% | -16.9% | +70.5% | +23.6% | – | |
| – | -13.7% | +45.0% | -2.8% | -17.1% | +250.2% | -8.5% | +12.8% | -5.2% | +20.7% | +8.9% | +3.8% | – | |
| – | -9.2% | +8.6% | +5.8% | +15.4% | +121.7% | +13.0% | -25.8% | +17.9% | +7.9% | +32.2% | +15.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1,083.2% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | +100.0% | -50.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.